Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis

Table 4

Effect of azilsartan (Azil) and placebo on TNF-α, IL-1β, IL-6 and anti-CCP levels and the clinical evaluation scores of patients with active RA maintained on methotrexate (MTX).

Inflammatory; marker	MTX + placebo,		MTX + Azil,
	Baseline	After 90 days	Baseline	After 90 days
TNF-α (pg/ml)
IL-1β (pg/ml)
IL-6 (pg/ml)
Anti-CCP (IU/ml)

Values are presented as mean ± SD; = number of patients; different compared to pretreatment within the same group ; values with different superscripts (a, b, and c) among groups are significantly different .